Jazz Pharmaceuticals

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Retrieved on: 
Monday, July 3, 2023
CD19, Takeda, Osteoporosis, CD20, Neoplasm, Biogen, VEGF, Patient, Epitope, Epithelial cell adhesion molecule, Zymeworks, Therapy, Lonza, Bone marrow, Research, Genentech, Gilead, EMA, Boehringer Ingelheim, ABL, Growth, ADC, PD-1, FDA, III, NMPA, Hubert Mordek, Roche, Docetaxel, Bispecific monoclonal antibody, Gilead Sciences, CD3, IGM, HER2, Immunoglobulin M, Conjugation, Cancer, Macrogen, Dragonfly, NSCLC, Antibody, Immunotherapy, Acute myeloid leukemia, CD33, Syndrome, Immune system, Pembrolizumab, Economics, Caris, Jazz, PRV, CEA, Diffuse large B-cell lymphoma, NHL, LAS, MDS, AML, CD123, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, BCMA, Vaccine, Fine chemical, Pharmaceutical industry, WNT

LAS VEGAS, July 3, 2023 /PRNewswire/ -- DelveInsight's 'Bispecific Antibody Competitive Landscape – 2023' report provides comprehensive global coverage of available, marketed, and pipeline bispecific antibodies in various stages of clinical development, major pharmaceutical companies working to advance the pipeline space, company assessment, comparative assessment, and future growth potential of the bispecific antibody competitive domain.

Key Points: 
  • The bispecific antibody pipeline and clinical trial analysis report deliver important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
  • Over 250+ bispecific antibody companies are evaluating 300+ bispecific antibody drugs in various stages of development, and their anticipated acceptance in the bispecific antibody market would significantly increase market revenue.
  • Promising bispecific antibody pipeline drugs such as Amivantamab, Blinatumomab, Ivonescimab, Zanidatamab, Glofitamab, Imvotamab, MGD024, PRV 3279, KN-046, SI-B001, REGN-5458, BI-905711, and others are under different phases of bispecific antibody clinical trials.
  • The collaboration is intended to help in the development and manufacturing of ABL Bio's new bispecific antibody product.

RADIOPHARMACY NETWORK RLS ANNOUNCES EXECUTIVE APPOINTMENTS IN SALES AND HUMAN RESOURCES

Retrieved on: 
Wednesday, June 21, 2023
Psychology, Human resources, Computerized Airline Sales and Marketing Association, University, Pharmacy, Come, PET, DePaul University, Bristol Myers Squibb, MBA, Marketing, Science, Samford University, Pharmacist, CDMO, Janet, Partner, Patient, The Industrial Pioneer, Jazz Pharmaceuticals, RLS, Development, Management, Pharmaceutical industry

LAKE ZURICH, Ill., June 21, 2023 /PRNewswire/ -- Today, RLS (USA), Inc. (Radioisotope Life Sciences), the third-largest nuclear medicine pharmacy network in the US, announced the appointments of Janet Otts-Watson as Vice President of Sales and Marketing, and Renee Wolf as Executive Director of Human Resources. The recent hires mark the latest step in RLS's continued efforts to expand capabilities, enter new markets and partner with industry-leading radiopharmaceutical suppliers to improve the continuum of care for patients across the country.

Key Points: 
  • "With Janet leading sales and Renee spearheading human resources, RLS is taking the next step toward long-term, sustainable growth."
  • As Vice President of Sales and Marketing, Otts-Watson will drive sales growth as RLS continues to enter new markets and expand offerings, ranging from CDMO work and clinical trials to PET and patient dose distribution.
  • In her role as Executive Director of Human Resources, Renee Wolf will lead people management across the RLS network, which includes 31 pharmacies nationwide.
  • Wolf joined RLS after most recently serving as Vice President of Human Resources for Drake Capital Solutions.

Autolus Therapeutics strengthens its Board with the appointment of Dr. Robert Iannone as a Non-Executive Director

Retrieved on: 
Tuesday, June 20, 2023
Yale University, Drug development, University, Senior, ALL, Acute lymphoblastic leukemia, Head, Merck & Co., University of Pennsylvania, Global production network, AstraZeneca, Bangladesh Technical Education Board, Assistant, Government, Research and development, Biomarker, CAR, Development, Johns Hopkins University, Patient, Fellow, Senior management, Knowledge, Jazz Pharmaceuticals, Merck, Pediatric Hematology and Oncology, Therapy, BLA, Annual general meeting, Pharmaceutical industry, Nursing, Pediatrics, Research

Dr. Iannone will serve as a Class I Director, with an initial term expiring at Autolus’ 2025 Annual General Meeting.

Key Points: 
  • Dr. Iannone will serve as a Class I Director, with an initial term expiring at Autolus’ 2025 Annual General Meeting.
  • Prior to then, Dr. Iannone served as Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine.
  • He currently serves on the Board of Directors of iTeos Therapeutics and previously served on the Board of Directors of Jounce Therapeutics (acquired by Concentra Biosciences in 2023 for $96.46 million).
  • He completed his Residency and Chief Residency in Pediatrics and a Fellowship in Pediatric Hematology-Oncology at Johns Hopkins University.

Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources

Retrieved on: 
Wednesday, June 14, 2023
Human resources, Senior, General counsel, Mitsubishi Carisma, Human, Idorsia, Jazz Pharmaceuticals, Patient, Corporation, Cancer, CARM, HR, Therapy, Pharmaceutical industry, Management

PHILADELPHIA, June 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma Therapeutics" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced leadership updates today. Eric Siegel has been appointed General Counsel and Corporate Secretary and Terry Shields has been named Senior Vice President of Human Resources. Prior to joining Carisma Therapeutics, Mr. Siegel was Chief Compliance Officer for Idorsia Pharmaceuticals US Inc. Ms. Shields is joining the Carisma Therapeutics team after 25 years of experience as a human resources consultant for start-up and fast-growth life science companies and four years as a consultant for Carisma Therapeutics.

Key Points: 
  • PHILADELPHIA, June 14, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma Therapeutics" or the "Company"), a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced leadership updates today.
  • Eric Siegel has been appointed General Counsel and Corporate Secretary and Terry Shields has been named Senior Vice President of Human Resources.
  • Prior to joining Carisma Therapeutics, Mr. Siegel was Chief Compliance Officer for Idorsia Pharmaceuticals US Inc. Ms. Shields is joining the Carisma Therapeutics team after 25 years of experience as a human resources consultant for start-up and fast-growth life science companies and four years as a consultant for Carisma Therapeutics.
  • "Having had the opportunity to work with Carisma the past four years, I am confident moving into this role will be a smooth transition and I am looking forward to continuing to support the team in this new position," said Terry Shields, Senior Vice President, Human Resources at Carisma Therapeutics.

LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, June 8, 2023
CLL, LAVA, Chronic lymphocytic leukemia, Bank statement, Multiple myeloma, LD, Cancer, Janssen, Robin, Gentium, Research, Acute myeloid leukemia, AML, Patient, Investment, MM, Exhibit, Jazz Pharmaceuticals, Form 6-K, Regulatory affairs, SVP, Therapy, PSA, Pharmaceutical industry, Vaccine, Fine chemical, Cryptocurrency, Video game, Seagen

“We entered 2023 with a strengthened leadership team and have laid the foundation for a productive year,” said Stephen Hurly, president and chief executive officer of LAVA Therapeutics.

Key Points: 
  • “We entered 2023 with a strengthened leadership team and have laid the foundation for a productive year,” said Stephen Hurly, president and chief executive officer of LAVA Therapeutics.
  • The financial information provided below reflects changes made to previously issued consolidated financial statements to revise immaterial prior-period misstatements.
  • Research and development expenses were $9.9 million for the quarter ended March 31, 2023, compared to $7.5 million for the quarter ended March 31, 2022.
  • General and administrative expenses were $3.9 million for the quarter ended March 31, 2023, compared to $4.2 million for the quarter ended March 31, 2022.

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Retrieved on: 
Saturday, June 3, 2023
Neoplasm, KOL, ICR, Progression-free survival, HER2, DOR, American Society of Clinical Oncology, RECIST, Research, Gallbladder cancer, PFS, IHC, ASCO, The Lancet, University, Annual general meeting, Corr, Kaplan–Meier estimator, In situ hybridization, Immunohistochemistry, Jazz Pharmaceuticals, BTC, Therapy, Society, ORR, Safety, Disease, Nursing, Medical imaging, Pharmaceutical industry, Patient

DUBLIN and VANCOUVER, BC, June 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.

Key Points: 
  • The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology .
  • The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
  • The KM estimated median PFS was 5.5 months [95% CI: 3.7, 7.2] with a range of 0.3 to 18.5 months.
  • Results of the pivotal HERIZON-BTC-01 trial (NCT04466891) indicate that the HER2-targeted, bispecific antibody zanidatamab demonstrates rapid, durable responses with a manageable safety profile in patients with treatment-refractory HER2-amplified BTC.

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Retrieved on: 
Friday, June 2, 2023
Neoplasm, KOL, ICR, Progression-free survival, HER2, DOR, American Society of Clinical Oncology, RECIST, Research, Gallbladder cancer, PFS, IHC, ASCO, The Lancet, University, Annual general meeting, Corr, Kaplan–Meier estimator, In situ hybridization, Immunohistochemistry, Jazz Pharmaceuticals, BTC, Therapy, Society, ORR, Safety, Disease, Nursing, Medical imaging, Pharmaceutical industry, Patient

DUBLIN and VANCOUVER, BC, June 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today presented positive pivotal trial data, including new data on progression-free survival (PFS), from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers (BTC). The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology. The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.

Key Points: 
  • The data were featured as an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in The Lancet Oncology .
  • The abstract (4008) was also selected to be included in the 2023 Best of ASCO® program, which will be held this summer following the ASCO Annual Meeting.
  • The KM estimated median PFS was 5.5 months [95% CI: 3.7, 7.2] with a range of 0.3 to 18.5 months.
  • Results of the pivotal HERIZON-BTC-01 trial (NCT04466891) indicate that the HER2-targeted, bispecific antibody zanidatamab demonstrates rapid, durable responses with a manageable safety profile in patients with treatment-refractory HER2-amplified BTC.

Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference

Retrieved on: 
Tuesday, May 30, 2023
Jazz Pharmaceuticals, Webcast, IST, Conference, Nightclub, Broadcasting

DUBLIN, May 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global Healthcare Conference.

Key Points: 
  • DUBLIN, May 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global Healthcare Conference.
  • Company management will participate in a fireside chat on Tuesday, June 13, 2023, at 3:20 p.m. PT / 11:20 p.m. IST.
  • An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com .
  • A replay of the webcast will be archived on the website for 30 days.

Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023

Retrieved on: 
Thursday, May 25, 2023
MBBS, Therapy, IST, Jazz Pharmaceuticals, Research, MD Anderson Cancer Center, ASCO, Interest, American Society of Clinical Oncology, Patient, University, Cancer, Annual general meeting, Corr, BTC, Society, Safety, Pharmaceutical industry, Webcast

DUBLIN, May 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a webcast to review the zanidatamab biliary tract cancers (BTC) data being featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2023. Previously disclosed positive top-line findings from the pivotal Phase 2b trial of zanidatamab as a monotherapy demonstrated a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-positive BTC. The ASCO presentation will provide additional safety and efficacy data.

Key Points: 
  • Webcast to follow on June 2, 2023 at 6:45 p.m. CT
    DUBLIN, May 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a webcast to review the zanidatamab biliary tract cancers (BTC) data being featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2023.
  • The webcast will start on June 2, 2023, at 6:45 p.m. CT / 7:45 p.m.
  • Interested parties may register for the webcast in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com .
  • To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.